$598 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 81 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Exit | OUTBRAIN INC | $0 | – | -12,148 | -100.0% | -0.01% | – | |
| Exit | 89BIO INCcall | $0 | – | -3,600 | -100.0% | -0.01% | – | |
| MGIC | Exit | MAGIC SOFTWARE ENTERPRISES Lord | $0 | – | -21,981 | -100.0% | -0.08% | – |
| TBLA | Exit | TABOOLA.COM LTD | $0 | – | -120,000 | -100.0% | -0.08% | – |
| Exit | NICE SYS INCnote 1.250% 1/1 | $0 | – | -250,000 | -100.0% | -0.12% | – | |
| AMAT | Exit | APPLIED MATLS INC | $0 | – | -8,499 | -100.0% | -0.18% | – |
| AUTL | Exit | AUTOLUS THERAPEUTICS PLCspon ads | $0 | – | -500,000 | -100.0% | -0.20% | – |
| BCAB | Exit | BIOATLA INC | $0 | – | -186,600 | -100.0% | -0.33% | – |
| STOK | Exit | STOKE THERAPEUTICS INC | $0 | – | -188,640 | -100.0% | -0.37% | – |
| ETNB | Exit | 89BIO INC | $0 | – | -180,600 | -100.0% | -0.49% | – |
| Exit | APELLIS PHARMACEUTICALS INCput | $0 | – | -60,000 | -100.0% | -0.67% | – | |
| Exit | LEONARDO DRS INC | $0 | – | -335,557 | -100.0% | -0.92% | – | |
| GNRC | Exit | GENERAC HLDGS INC | $0 | – | -50,000 | -100.0% | -1.08% | – |
| XBI | Exit | SPDR SER TRs&p biotech | $0 | – | -70,000 | -100.0% | -1.25% | – |
| CNCE | Exit | CONCERT PHARMACEUTICALS INC | $0 | – | -1,002,783 | -100.0% | -1.26% | – |
| FIVN | Exit | FIVE9 INC | $0 | – | -95,000 | -100.0% | -1.38% | – |
| Exit | CINCOR PHARMA INC | $0 | – | -529,640 | -100.0% | -1.40% | – | |
| Exit | TOWER SEMICONDUCTOR LTDput | $0 | – | -161,600 | -100.0% | -1.50% | – | |
| ALBO | Exit | ALBIREO PHARMA INC | $0 | – | -463,828 | -100.0% | -2.15% | – |
| Exit | TEVA PHARMACEUTICAL INDS LTDcall | $0 | – | -2,222,300 | -100.0% | -4.35% | – | |
| Exit | INVESCO QQQ TRput | $0 | – | -210,000 | -100.0% | -12.00% | – | |
| Exit | INVESCO QQQ TRcall | $0 | – | -231,000 | -100.0% | -13.20% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
| SC 13G | 2023-08-30 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.